These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 31217169)

  • 1. Non-response to rituximab therapy in rheumatoid arthritis is associated with incomplete disruption of the B cell receptor repertoire.
    Pollastro S; Klarenbeek PL; Doorenspleet ME; van Schaik BDC; Esveldt REE; Thurlings RM; Boumans MJH; Gerlag DM; Tak PP; Vos K; Baas F; van Kampen AHC; de Vries N
    Ann Rheum Dis; 2019 Oct; 78(10):1339-1345. PubMed ID: 31217169
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sensitive B-cell receptor repertoire analysis shows repopulation correlates with clinical response to rituximab in rheumatoid arthritis.
    Pollastro S; Musters A; Balzaretti G; Niewold I; van Schaik B; Hässler S; Verhoef CM; Pallardy M; van Kampen A; Mariette X; de Vries N;
    Arthritis Res Ther; 2024 Mar; 26(1):70. PubMed ID: 38493208
    [TBL] [Abstract][Full Text] [Related]  

  • 3. B cell depletion with rituximab in patients with rheumatoid arthritis: Multiplex bead array reveals the kinetics of IgG and IgA antibodies to citrullinated antigens.
    Cambridge G; Leandro MJ; Lahey LJ; Fairhead T; Robinson WH; Sokolove J
    J Autoimmun; 2016 Jun; 70():22-30. PubMed ID: 27055777
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IL-40: A New B Cell-Associated Cytokine Up-Regulated in Rheumatoid Arthritis Decreases Following the Rituximab Therapy and Correlates With Disease Activity, Autoantibodies, and NETosis.
    Navrátilová A; Andrés Cerezo L; Hulejová H; Bečvář V; Tomčík M; Komarc M; Veigl D; Tegzová D; Závada J; Olejárová M; Pavelka K; Vencovský J; Šenolt L
    Front Immunol; 2021; 12():745523. PubMed ID: 34745117
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Longterm effects of rituximab on B cell counts and autoantibody production in rheumatoid arthritis: use of high-sensitivity flow cytometry for more sensitive assessment of B cell depletion.
    Váncsa A; Szabó Z; Szamosi S; Bodnár N; Végh E; Gergely L; Szucs G; Szántó S; Szekanecz Z
    J Rheumatol; 2013 May; 40(5):565-71. PubMed ID: 23547216
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dominant B cell receptor clones in peripheral blood predict onset of arthritis in individuals at risk for rheumatoid arthritis.
    Tak PP; Doorenspleet ME; de Hair MJH; Klarenbeek PL; van Beers-Tas MH; van Kampen AHC; van Schaardenburg D; Gerlag DM; Baas F; de Vries N
    Ann Rheum Dis; 2017 Nov; 76(11):1924-1930. PubMed ID: 28790026
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rheumatoid arthritis synovial tissue harbours dominant B-cell and plasma-cell clones associated with autoreactivity.
    Doorenspleet ME; Klarenbeek PL; de Hair MJ; van Schaik BD; Esveldt RE; van Kampen AH; Gerlag DM; Musters A; Baas F; Tak PP; de Vries N
    Ann Rheum Dis; 2014 Apr; 73(4):756-62. PubMed ID: 23606709
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of rituximab's immunomodulatory synovial effects (ARISE trial). 1: clinical and synovial biomarker results.
    Kavanaugh A; Rosengren S; Lee SJ; Hammaker D; Firestein GS; Kalunian K; Wei N; Boyle DL
    Ann Rheum Dis; 2008 Mar; 67(3):402-8. PubMed ID: 17644541
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of nonresponse to rituximab in rheumatoid arthritis: predictors and outcome of re-treatment.
    Vital EM; Dass S; Rawstron AC; Buch MH; Goëb V; Henshaw K; Ponchel F; Emery P
    Arthritis Rheum; 2010 May; 62(5):1273-9. PubMed ID: 20131284
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation between cellular expression of complement regulatory proteins with depletion and repopulation of B-lymphocytes in peripheral blood of patients with rheumatoid arthritis treated with rituximab.
    Viecceli D; Garcia MP; Schneider L; Alegretti AP; Silva CK; Ribeiro AL; Brenol CV; Xavier RM
    Rev Bras Reumatol Engl Ed; 2017; 57(5):385-391. PubMed ID: 29037309
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Residual inflammation after rituximab treatment is associated with sustained synovial plasma cell infiltration and enhanced B cell repopulation.
    Teng YK; Levarht EW; Toes RE; Huizinga TW; van Laar JM
    Ann Rheum Dis; 2009 Jun; 68(6):1011-6. PubMed ID: 18647852
    [TBL] [Abstract][Full Text] [Related]  

  • 12. B-cell imaging with zirconium-89 labelled rituximab PET-CT at baseline is associated with therapeutic response 24 weeks after initiation of rituximab treatment in rheumatoid arthritis patients.
    Bruijnen S; Tsang-A-Sjoe M; Raterman H; Ramwadhdoebe T; Vugts D; van Dongen G; Huisman M; Hoekstra O; Tak PP; Voskuyl A; van der Laken C
    Arthritis Res Ther; 2016 Nov; 18(1):266. PubMed ID: 27863504
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of Rituximab and Infliximab Treatment on Carboxypeptidase B and Its Substrates in RA Synovium.
    Edginton S; Hitchon C; Froese W; El-Gabalawy H
    J Rheumatol; 2016 May; 43(5):846-54. PubMed ID: 26932340
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In Human Autoimmunity, a Substantial Component of the B Cell Repertoire Consists of Polyclonal, Barely Mutated IgG
    Cowan GJM; Miles K; Capitani L; Giguere SSB; Johnsson H; Goodyear C; McInnes IB; Breusch S; Gray D; Gray M
    Front Immunol; 2020; 11():395. PubMed ID: 32265907
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis.
    Leandro MJ; Cambridge G; Ehrenstein MR; Edwards JC
    Arthritis Rheum; 2006 Feb; 54(2):613-20. PubMed ID: 16447239
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synovial tissue response to rituximab: mechanism of action and identification of biomarkers of response.
    Thurlings RM; Vos K; Wijbrandts CA; Zwinderman AH; Gerlag DM; Tak PP
    Ann Rheum Dis; 2008 Jul; 67(7):917-25. PubMed ID: 17965121
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An extra dose of rituximab improves clinical response in rheumatoid arthritis patients with initial incomplete B cell depletion: a randomised controlled trial.
    Vital EM; Dass S; Buch MH; Rawstron AC; Emery P
    Ann Rheum Dis; 2015 Jun; 74(6):1195-201. PubMed ID: 24443001
    [TBL] [Abstract][Full Text] [Related]  

  • 18. B cell repopulation kinetics after rituximab treatment in ANCA-associated vasculitides compared to rheumatoid arthritis, and connective tissue diseases: a longitudinal observational study on 120 patients.
    Thiel J; Rizzi M; Engesser M; Dufner AK; Troilo A; Lorenzetti R; Voll RE; Venhoff N
    Arthritis Res Ther; 2017 May; 19(1):101. PubMed ID: 28521808
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CCL19, a B cell chemokine, is related to the decrease of blood memory B cells and predicts the clinical response to rituximab in patients with rheumatoid arthritis.
    Sellam J; Rouanet S; Hendel-Chavez H; Miceli-Richard C; Combe B; Sibilia J; Le Loët X; Tebib J; Jourdan R; Dougados M; Taoufik Y; Mariette X
    Arthritis Rheum; 2013 Sep; 65(9):2253-61. PubMed ID: 23740460
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early effects of rituximab on the synovial cell infiltrate in patients with rheumatoid arthritis.
    Vos K; Thurlings RM; Wijbrandts CA; van Schaardenburg D; Gerlag DM; Tak PP
    Arthritis Rheum; 2007 Mar; 56(3):772-8. PubMed ID: 17328049
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.